EN DE
Watch Mezzion Pharma Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mezzion Pharma Co.Ltd (140410) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Mezzion Pharma Co.Ltd stock KRW 31,450, price KRW 65,600, that is 52.1% below the price, quality 27 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7140410002

MP Mezzion Pharma Co.Ltd logo Thin data Nov 10, 2026

Mezzion Pharma Co.Ltd

140410 · KQ
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Low debt
Fair value 31,450 KRW · Strongly overvalued
Quality 27/100
Weak Growth (revenue 5y −22.7 %/yr in KRW)
Loss-making · -81.7% net margin (TTM)
Negative free cash flow
Trails peers (2/8)
Narrow moat 9/100
Thin data
Estimate
Watch Mezzion Pharma Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

172,700 KRW 12,450 KRW Fair Value 31,450 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 12,450 KRW – 172,700 KRW · fair‑value band 23,587 KRW – 39,312 KRW · the 65,600 KRW price screens above the 31,450 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Mezzion Pharma Co.Ltd in your weekly email

Every Wednesday you see whether Mezzion Pharma Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases.

Show moreShow less

It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases.

The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Stock analysis

Mezzion Pharma Co.Ltd (140410) currently trades at 65,600 KRW, while our estimate is 31,450 KRW, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 23,587 KRW (bear) to 39,312 KRW (bull), the price of 65,600 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Mezzion Pharma Co.Ltd reported revenue of 7.9B KRW in FY2025 versus 26.7B KRW in FY2021, a compound −26.2%/yr. Reported net income was −34.9B KRW in FY2025.

Key figures

Market cap 2.0T KRW (≈ $1.5B) Small · P/S ratio 53.0 · Net margin −81.7% · Return on equity −4,526% · Return on assets (EBIT) −23.0% (5-year average) · Operating margin −69.3% · Revenue growth (YoY) +13.6% · Free cash flow −29.9B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −52%, 140410 screens richer than that median.

Fair Value

Bear 23,587 KRW Fair Value 31,450 KRW Bull 39,312 KRW
Price 65,600 KRW · Downside -52.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 29
Distance to the 52-week high, does not count
New shares 56
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.7%
Start year 2020 (pandemic). Over 10 years: −6.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.3% (2020) → −212.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

140410 screens overvalued: fair value 52% below the price. Compare with ST Pharm Co →

Compare Mezzion Pharma Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −52.1% · Bottom 25%
Profitability
Return on assets −35.6% · Bottom 25%
Net margin (12 months) −81.7% · Bottom 25%
Operating margin (12 months) −69.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 13.6% · Above median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/S (12 months) 65.61× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)68 · sector 51
PAST (return on equity)0 · sector 10
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,750 KRW 47,019 KRW +138% vs 140410
DongKook Pharmaceutical Co 086450 24,750 KRW 28,372 KRW +15% vs 140410
VIKRAMTH VIKRAMTH ₹324.45 ₹356.90 +10% vs 140410
ST Pharm Co 237690 75,500 KRW 61,182 KRW −19% vs 140410
Vivozon Pharmaceutical Co 082800 3,000 KRW 2,150 KRW −28% vs 140410
Oscotec Inc 039200 36,050 KRW 21,262 KRW −41% vs 140410
NatureCell Co 007390 20,550 KRW 10,696 KRW −48% vs 140410
BINEX Co 053030 6,330 KRW 1,844 KRW −71% vs 140410
Caregen Co 214370 27,000 KRW 5,414 KRW −80% vs 140410
SHUKRAPHAR SHUKRAPHAR ₹82.11 ₹9.14 −89% vs 140410

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mezzion Pharma Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mezzion Pharma Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/140410

Frequently asked questions

Is Mezzion Pharma Co.Ltd (140410) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 31,450 KRW versus a price of 65,600 KRW, about 52% lower (overvalued).
What is the fair value of 140410?
Our estimate for Mezzion Pharma Co.Ltd is 31,450 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 65,600 KRW.
What is the quality score of 140410?
Mezzion Pharma Co.Ltd has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mezzion Pharma Co.Ltd (140410)?
Our calculated price target is the estimate of 31,450 KRW (as of Nov 10, 2026). Cautious scenario 23,587 KRW, optimistic scenario 39,312 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Mezzion Pharma Co.Ltd stock forecast for 2026?
Our estimate puts fair value at 31,450 KRW, about 52% lower versus a price of 65,600 KRW (overvalued). Cautious scenario 23,587 KRW, optimistic scenario 39,312 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Mezzion Pharma Co.Ltd (140410)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mezzion Pharma Co.Ltd it is 31,450 KRW per share (as of Nov 10, 2026), against a price of 65,600 KRW.
Is Mezzion Pharma Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 140410 trades above its calculated fair value: price 65,600 KRW, fair value 31,450 KRW, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 140410?
No. The price is what the market pays today (65,600 KRW); the fair value is what the company's own numbers justify (31,450 KRW). For Mezzion Pharma Co.Ltd the two are 34,150 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Mezzion Pharma Co.Ltd worth?
The market values Mezzion Pharma Co.Ltd at about 2.0T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 65,600 KRW; our models calculate a fair value of 31,450 KRW per share.
What do the bullish and bearish scenarios say about 140410?
Our models span a range for Mezzion Pharma Co.Ltd: cautious scenario 23,587 KRW, base 31,450 KRW, optimistic 39,312 KRW per share (as of Nov 10, 2026, price 65,600 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 140410 from its 52-week high?
Mezzion Pharma Co.Ltd trades at 65,600 KRW, about 62% below its 52-week high of 172,700 KRW and 31% above the low of 49,900 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 31,450 KRW is for.
Which stocks are comparable to Mezzion Pharma Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, NatureCell Co, Oscotec Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mezzion Pharma Co.Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 65,600 KRW, calculated fair value 31,450 KRW (−52%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Mezzion Pharma Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mezzion Pharma Co.Ltd (140410)?
The closing price on Nov 10, 2026 was 65,600 KRW. Our estimate is 31,450 KRW, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mezzion Pharma Co.Ltd right now?
The price sits above even our optimistic bull case (39,312 KRW). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Mezzion Pharma Co.Ltd

How large is the market capitalisation of Mezzion Pharma Co.Ltd (140410)?
The market capitalisation of Mezzion Pharma Co.Ltd is 2.0T KRW (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mezzion Pharma Co.Ltd (140410)?
The price-to-sales ratio of Mezzion Pharma Co.Ltd is 53.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Mezzion Pharma Co.Ltd (140410)?
The net margin of Mezzion Pharma Co.Ltd is −81.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mezzion Pharma Co.Ltd (140410)?
The return on equity (ROE) of Mezzion Pharma Co.Ltd is −4,526% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mezzion Pharma Co.Ltd (140410)?
On an EBIT basis the return on assets of Mezzion Pharma Co.Ltd is −23.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mezzion Pharma Co.Ltd (140410)?
The operating margin of Mezzion Pharma Co.Ltd is −69.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mezzion Pharma Co.Ltd (140410)?
Revenue at Mezzion Pharma Co.Ltd is growing +13.6% versus a year earlier (3y avg −36.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mezzion Pharma Co.Ltd (140410) generate?
The free cash flow of Mezzion Pharma Co.Ltd is −29.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Mezzion Pharma Co.Ltd in the live analysis

One click puts Mezzion Pharma Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.